|
Variable
|
Exposed
|
Unexposed
|
Unadjusted
|
Adjusted*
|
|---|
| |
n
|
Rate‡
|
95% CI
|
n
|
Rate‡
|
95% CI
|
Hazard ratio
|
95% CI
|
Hazard ratio
|
95% CI
|
|---|
|
1-Year landmark
| | | | | | | | | | |
|
Overall
|
674
|
34.3
|
31.8, 37.0
|
4058
|
23.3
|
22.6, 24.0
|
1.47
|
1.35, 1.59
|
1.09
|
0.99, 1.18
|
|
Male
|
450
|
26.4
|
24.1, 28.9
|
2878
|
19.8
|
19.1, 20.5
|
1.33
|
1.21, 1.47
|
1.08
|
0.98, 1.20
|
|
Female
|
224
|
86.7
|
76.1, 98.9
|
1180
|
41.0
|
38.7, 43.4
|
2.01
|
1.74, 2.32
|
1.11
|
0.96, 1.29
|
|
3-Year landmark
|
|
Overall
|
549
|
26.1
|
24.0, 28.4
|
2027
|
19.3
|
18.4, 20.1
|
1.35
|
1.23, 1.49
|
1.03
|
0.94, 1.14
|
|
Male
|
390
|
20.7
|
18.8, 22.9
|
1538
|
17.5
|
16.6, 18.4
|
1.19
|
1.06, 1.33
|
0.96
|
0.85, 1.07
|
|
Female
|
159
|
71.1
|
60.9, 83.1
|
489
|
28.3
|
25.9, 31.0
|
2.43
|
2.03, 2.90
|
1.31
|
1.09, 1.59
|
- CKD chronic kidney disease, ULT urate-lowering therapy
- *Adjusted for age, gender, body mass index, smoking status, diabetes mellitus, treated hypertension, rheumatoid arthritis, heart failure, index of multiple deprivation, myocardial infarction, cerebrovascular disease, peripheral vascular disease, history of hospitalisation, non-steroidal anti-inflammatory drug exposure and baseline serum creatine and uric acid, when not stratified by them. ‡ per 10,000 person-years
